[Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study].

The efficacy of an extract of Pygeum africanum in the treatment of micturitional disorders due to benign prostatic hyperplasia was tested in a multicentre double-blind trial versus placebo. Capsules containing 50 mg of Pygeum africanum extract or placebo were administered at a dosage of 1 capsule in the morning and 1 capsule in the evening over a period of 60 days. 263 patients were included in this study, which was carried out in 8 centres in Germany, France, and Austria.

[Long-term intravesical treatment with adriamycin in chemoprevention of recurrence of transurethrally resected urinary bladder cancers].

64 patients with a histologically verified urothelial tumour of the urinary bladder were given intravesical Adriamycin-instillations after transurethral resection of their tumours. 34 patients received 50 mg Adriamycin once weekly for a period of 6 weeks. 30 patients, after undergoing this initial treatment, were treated with 50 mg Adriamycin once a month over a period of 2 years.

[Adjuvant topical chemotherapy with cisplatin in superficial bladder cancer].

During a period of 6 weeks we applied a weekly dosage of 50 mg of cis-platinum as an intravesical instillation treatment to 30 patients with superficial carcinomas of the urinary bladder. Prior to this treatment these patients had undergone a transurethral differentiated resection of their tumours by multiple biopsies (mapping). Persistent tumours were found in 3 patients (10%).

Prophylactic use of topical adriamycin after transurethral resection of transitional cell bladder tumours.

Thirty-five patients with carcinoma of the bladder were subjected to weekly intravesical instillation treatment with 30 mg adriamycin/50 ml solution for a period of 6 weeks following transurethral resection of the tumour. The oncolytic and thus recurrence-preventive value of treatment was determined by endoscopic controls with exploratory excisions and exfoliative cytology. All in all, a recurrence-free rate was found in 77% over a minimum observation period of one year.

[Prevention of recurrence in urinary bladder tumors by intravesical instillation treatment with adriamycin].

109 patients with urinary bladder cancer received post TUR treatment with weekly intravesical instillations of Adriamycin for a period of 6 weeks. 32 patients received a dosage of 10 mg/50 ml physiological NaCl, 35 patients a dosage of 30 mg/50 ml physiological NaCl. We determined the oncolytical value and the value of prophylactically reduced recurrence through urine cytology and endoscopic controls with biopsies.